Von Willebrand factor's clearance

被引:0
|
作者
Denis, Cecile V. [1 ]
Lenting, Peter J. [2 ]
机构
[1] INSERM, Unite 143, 80 Rue General Leclerc, F-94276 Le Kremlin Bicetre, France
[2] Univ Med Ctr Utrecht, Dept Haematol, Lab Thrombosis & Haemostasis, Utrecht, Netherlands
来源
HEMATOLOGIE | 2006年 / 12卷 / 01期
关键词
von Willebrand factor; von Willebrand disease; clearance; gene modifier; mutations; in vivo models;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand factor (FVW) is a multimeric plasma glycoprotein that plays two major roles in hemostasis: it promotes platelet adhesion to the subendothelium in case of vascular injury and it carries and protects coagulation FVIII in the circulation. FVW plasma concentration requires tight regulation since a reduced level may result in a bleeding tendency whereas an elevated concentration is associated with an increased thrombotic risk. Plasma levels represent a balance between biosynthetic and catabolic pathways. With regard to FVW, its biosynthetic pathways has been well studied in the past while relatively little is known concerning its clearance mechanism. However, recent data point to abnormal clearance as being a potential cause for von Willebrand disease, the most common inherited bleeding disorder in humans. Defective clearance may originate from a variety of reasons: mutations in the FVW gene, effect of a gene modifier or increase functionality of the FVW clearance mechanism. In this review, we will give an update of the present knowledge on how FVW is cleared from the circulation and how this process is regulated.
引用
收藏
页码:34 / 43
页数:10
相关论文
共 50 条
  • [31] The von Willebrand factor propolypeptide, von Willebrand antigen II (vWAgII), distinguishes acquired von Willebrand syndrome (AvWS) due to decreased synthesis of von Willebrand factor (vWF) from AvWS due to increased clearance of vWF.
    Scott, JP
    Vokac, EA
    Schroeder, T
    Foster, PA
    Gill, JC
    Montgomery, PR
    BLOOD, 1995, 86 (10) : 773 - 773
  • [32] Detection of non-inhibitory binding antibodies to von Willebrand factor affecting the clearance of VWF:Ag in von Willebrand disease
    Suiter, T. M.
    Mannucci, P. M.
    Kempton, C. L.
    Laffan, M.
    Romond, E. H.
    Shapiro, A. D.
    Birschmann, I.
    Ragni, M. V.
    Gill, J. C.
    Klamroth, R.
    Reipert, B. M.
    Turecek, P. L.
    Varadi, K.
    Chapman, M.
    Engl, W.
    Ewenstein, B. M.
    HAEMOPHILIA, 2012, 18 : 200 - 200
  • [33] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN DELAYS CLEARANCE OF VON-WILLEBRAND-FACTOR IN ACQUIRED VON-WILLEBRAND DISEASE
    VANGENDEREN, PJJ
    TERPSTRA, W
    MICHIELS, JJ
    KAPTEIJN, L
    VANVLIET, HHDM
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (05) : 891 - 892
  • [34] von Willebrand factor
    Ruggeri, ZM
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04): : 559 - 564
  • [35] Von Willebrand factor
    Bhogal, Pervinder
    Jensen, Melanie
    Hart, Dan
    Makalanda, Levansri
    Collins, George B.
    Spooner, Oliver
    Jaffer, Ounali
    CLINICAL MEDICINE, 2020, 20 (06) : E279 - E279
  • [36] von Willebrand factor
    Ruggeri, ZM
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11): : S41 - S46
  • [37] Laboratory assays for von Willebrand factor: Relative contribution to the diagnosis of von Willebrand's disease
    Favaloro, EJ
    Koutts, J
    PATHOLOGY, 1997, 29 (04) : 385 - 391
  • [38] Von Willebrand factor
    Ruggeri, ZM
    CURRENT OPINION IN HEMATOLOGY, 2003, 10 (02) : 142 - 149
  • [39] Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations
    Castaman, Giancarlo
    Tosetto, Alberto
    Rodeghiero, Francesco
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06): : 963 - 969
  • [40] von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease
    Vischer, UM
    de Moerloose, P
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 30 (02) : 93 - 109